ATE456100T1 - Zusammensetzungen und verfahren im zusammenhang mit der nuklearen hormon-rezeptor-stelle ii - Google Patents
Zusammensetzungen und verfahren im zusammenhang mit der nuklearen hormon-rezeptor-stelle iiInfo
- Publication number
- ATE456100T1 ATE456100T1 AT03765637T AT03765637T ATE456100T1 AT E456100 T1 ATE456100 T1 AT E456100T1 AT 03765637 T AT03765637 T AT 03765637T AT 03765637 T AT03765637 T AT 03765637T AT E456100 T1 ATE456100 T1 AT E456100T1
- Authority
- AT
- Austria
- Prior art keywords
- site
- nhrs
- modulators
- nuclear hormone
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39690702P | 2002-07-18 | 2002-07-18 | |
PCT/US2003/022299 WO2004009016A2 (en) | 2002-07-18 | 2003-07-17 | Compositions and methods involving nuclear hormone receptor site ii |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE456100T1 true ATE456100T1 (de) | 2010-02-15 |
Family
ID=30770956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03765637T ATE456100T1 (de) | 2002-07-18 | 2003-07-17 | Zusammensetzungen und verfahren im zusammenhang mit der nuklearen hormon-rezeptor-stelle ii |
Country Status (7)
Country | Link |
---|---|
US (1) | US7442554B2 (de) |
EP (1) | EP1575502B1 (de) |
AT (1) | ATE456100T1 (de) |
AU (1) | AU2003251969A1 (de) |
DE (1) | DE60331103D1 (de) |
ES (1) | ES2337679T3 (de) |
WO (1) | WO2004009016A2 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
WO2005012263A1 (en) * | 2003-07-24 | 2005-02-10 | Pharmagene Laboratories Limited | 5-ht2b receptor antagonists |
WO2005097113A2 (en) * | 2004-04-08 | 2005-10-20 | Pharmagene Laboratories Limited | 5-ht2b receptor antagonists |
AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
US7579335B2 (en) | 2005-01-10 | 2009-08-25 | Glaxo Group Limited | Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
PE20100737A1 (es) | 2005-03-25 | 2010-11-27 | Glaxo Group Ltd | Nuevos compuestos |
AR053450A1 (es) | 2005-03-25 | 2007-05-09 | Glaxo Group Ltd | Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38 |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
ES2448839T3 (es) | 2007-11-01 | 2014-03-17 | Bristol-Myers Squibb Company | Compuestos no esteroideos útiles como moderadores de la actividad del receptor de glucocorticoides AP-1 y/o NF-kappa b y uso de los mismos |
EP3020393B1 (de) | 2009-12-16 | 2020-10-07 | 3M Innovative Properties Company | Formulierungen und verfahren zur steuerung der mdi-partikelgrössenfreisetzung |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5759785A (en) | 1992-05-14 | 1998-06-02 | Baylor College Of Medicine | Method of identifying hormone antagonists and agonists |
US5856116A (en) * | 1994-06-17 | 1999-01-05 | Vertex Pharmaceuticals, Incorporated | Crystal structure and mutants of interleukin-1 beta converting enzyme |
AU717743B2 (en) | 1995-12-13 | 2000-03-30 | Regents Of The University Of California, The | Nuclear receptor ligands and ligand binding domains |
WO1999060014A2 (en) * | 1998-03-30 | 1999-11-25 | The Regents Of The University Of California | Methods and compounds for modulating nuclear receptor coactivator binding |
AU2818200A (en) * | 1999-03-01 | 2000-09-21 | Karo Bio Ab | Homology models of the glucocorticoid receptor |
AU2002355929A1 (en) | 2001-07-17 | 2003-03-03 | Smithkline Beecham Corporation | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
GB0209507D0 (en) * | 2002-04-25 | 2002-06-05 | Karobio Ab | Nuclear receptor structure |
EP1375517A1 (de) * | 2002-06-21 | 2004-01-02 | Smithkline Beecham Corporation | Struktur der Ligandenbindedomäne des Glucocorticoidrezeptors umfassend eine expandierte Bindetasche und Anwendungsverfahren |
AU2003251970A1 (en) | 2002-07-18 | 2004-02-09 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
-
2003
- 2003-07-17 EP EP03765637A patent/EP1575502B1/de not_active Expired - Lifetime
- 2003-07-17 ES ES03765637T patent/ES2337679T3/es not_active Expired - Lifetime
- 2003-07-17 AU AU2003251969A patent/AU2003251969A1/en not_active Abandoned
- 2003-07-17 US US10/621,807 patent/US7442554B2/en not_active Expired - Fee Related
- 2003-07-17 AT AT03765637T patent/ATE456100T1/de not_active IP Right Cessation
- 2003-07-17 WO PCT/US2003/022299 patent/WO2004009016A2/en not_active Application Discontinuation
- 2003-07-17 DE DE60331103T patent/DE60331103D1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2004009016A3 (en) | 2005-10-06 |
ES2337679T3 (es) | 2010-04-28 |
AU2003251969A1 (en) | 2004-02-09 |
US7442554B2 (en) | 2008-10-28 |
DE60331103D1 (de) | 2010-03-11 |
US20060223110A1 (en) | 2006-10-05 |
AU2003251969A8 (en) | 2004-02-09 |
EP1575502B1 (de) | 2010-01-20 |
EP1575502A2 (de) | 2005-09-21 |
WO2004009016A2 (en) | 2004-01-29 |
EP1575502A4 (de) | 2007-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Way | Endogenous and Exogenous Opiate Agonists and Antagonists: Proceedings of the International Narcotic Research Club Conference, June 11-15, 1979, North Falmouth, Massachusetts, USA | |
Carbonara | An Italian contribution to architectural restoration | |
ATE456100T1 (de) | Zusammensetzungen und verfahren im zusammenhang mit der nuklearen hormon-rezeptor-stelle ii | |
ATE507210T1 (de) | Chinazolinon modulatoren von nukleinrezeptoren | |
RS51602B (sr) | April receptor (bcma) i njegova upotreba | |
BRPI0512142A (pt) | método para o tratamento de uma formação subterránea, uso de um material, e, composição de tratamento de poço di hidrocarboneto | |
ATE521599T1 (de) | Heterocyclische modulatoren von nukleären rezeptoren | |
Reichardt et al. | Policy recommendations for enhanced resilience of aviation due to extreme volcanic ash eruptions | |
Hakim et al. | Tuberculosis Control Management: Implementation of DOTS (Directly Observed Treatment Short) Strategy in Achieving The Target of SDG’s 2030 | |
Hatem | Design-Build and Public-Private Partnerships: Risk Allocation of Subsurface Conditions | |
Diamond | Organic growth and the collective enterprise: Building on the work of Barbara Dockar-Drysdale to develop the new therapeutic task. | |
Rubtcova et al. | Service-Oriented Architecture for the Construction of Information System | |
Sutherland et al. | Scrum Log Jeff Sutherland | |
Keelor | Earth and Space Science Ph. D. Class of 2003 Report released | |
Caldwell | Rome Center Experts Direct Tumacacori Project | |
BARRY et al. | A flexible and scalable maintenance contract procurement method | |
Fehrsen | Whither Now? | |
DK1791868T3 (da) | Antistoffer, der binder til receptorer KIR2DL1, -2, 3 men ikke KIR2DS4, samt terapeutisk anvendelse | |
Kim Brown et al. | The following persons were in attendance at a meeting held on 7/16/09 in Washington, DC between DON and ATSDR: Brian Harrison, Naval Facilities Engineering Command (NAVFAC) HQ Mario Dumenigo, NAVFAC HQ | |
Bishop et al. | Mobile Computing and Education: (Panel) | |
Alintah-Abel et al. | Effect of COVID-19 pandemic on the cost of building materials in Nigeria | |
Neumann et al. | Archaeology and the Legislative Process: How Things Have Changed Over the Last Twenty Years | |
Oger et al. | CARAMANIAN ORTHODOX TURKS WHO IMMIGRATED TO GREECE FROM MUSTAFAPASHA BECAUSE OF THE POPULATION EXCHANGE | |
Mona | An analysis of historic preservation and planning policy in Milwaukee, 1964-1994 | |
Olver | Poverty, health and health care in South Africa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |